Complement‐mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective study

• Published in: European journal of haematology Vol. 112; no. 3; pp. 450 - 457
• Main Authors: Laber, Damian A., Patel, Parth C., Logothetis, Constantine N., Patel, Ankita K., Jaglal, Michael, Haider, Mintallah, Visweshwar, Nathan, Rajasekaran‐Rathnakumar, Geetha, Eatrides, Jennifer
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.03.2024
• Subjects: atypical hemolytic uremic syndrome; Atypical Hemolytic Uremic Syndrome - drug therapy; Atypical Hemolytic Uremic Syndrome - genetics; Complement Inactivator Proteins; Complement System Proteins; Creatinine; eculizumab; Genetic diversity; Glomerular filtration rate; Hemoglobin; Hemolytic uremic syndrome; Humans; L-Lactate dehydrogenase; Middle Aged; Monoclonal antibodies; Morbidity; Mortality; Patients; ravulizumab; Retrospective Studies; Thrombotic Microangiopathies - diagnosis; Thrombotic Microangiopathies - drug therapy; Thrombotic Microangiopathies - etiology; Thrombotic microangiopathy; atypical hemolytic uremic syndrome; eculizumab; thrombotic microangiopathy; ravulizumab

Background Complement‐mediated thrombotic microangiopathy (CM‐TMA), also called atypical hemolytic uremic syndrome (aHUS), is a difficult‐to‐diagnose rare disease that carries severe morbidity and mortality. Anti‐C5 monoclonal antibodies (aC5‐mab) are standard treatments, but large studies and long‐...